Novo Nordisk A/S $NVO Shares Acquired by RPG Investment Advisory LLC

RPG Investment Advisory LLC boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 13.1% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 152,574 shares of the company’s stock after purchasing an additional 17,662 shares during the period. RPG Investment Advisory LLC’s holdings in Novo Nordisk A/S were worth $8,466,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently added to or reduced their stakes in the stock. True Wealth Design LLC grew its position in shares of Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after acquiring an additional 300 shares during the last quarter. NewSquare Capital LLC lifted its position in Novo Nordisk A/S by 174.1% in the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. acquired a new position in Novo Nordisk A/S during the 2nd quarter valued at about $37,000. State of Wyoming bought a new position in Novo Nordisk A/S in the 1st quarter worth about $38,000. Finally, Maseco LLP bought a new position in Novo Nordisk A/S in the 2nd quarter worth about $39,000. 11.54% of the stock is currently owned by institutional investors.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: U.S. launch: Novo made the Wegovy pill broadly available across 70,000+ U.S. pharmacies with a subsidized self‑pay starting price (reported $149/month), positioning the first oral GLP‑1 for rapid patient uptake and widening access — a clear revenue catalyst. Novo Nordisk’s Wegovy pill now broadly available across America (PR Newswire)
• Positive Sentiment: Market reaction and coverage: Media and equity analysts flagged the pill’s U.S. launch as a potential catalyst to “rekindle momentum” for NVO shares and noted immediate stock upticks on the news. First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. (CNBC)
• Positive Sentiment: Unusual options flow: Traders bought ~131,266 call options (about +37% vs. normal), indicating short‑term bullish bets that could amplify upside if newsflow or early sales data are positive. (Options volume report)
• Neutral Sentiment: Regulatory outlook outside U.S.: The UK regulator is reviewing Novo’s oral Wegovy submission and could decide by year‑end — a potential incremental upside, but timing is uncertain. UK regulator could issue decision by year-end (Reuters)
• Neutral Sentiment: Valuation/return debate: Commentary pieces are weighing mixed historical returns against arguments that NVO remains undervalued — this frames investor expectations but doesn’t change near‑term sales dynamics. Valuation check after mixed returns (Yahoo Finance)
• Negative Sentiment: Executive departure: Novo’s U.S. head of public affairs has left, which raises near‑term communications and stakeholder‑management risk as the company scales a major product launch in its largest market. U.S. public affairs head leaves (Reuters)
• Negative Sentiment: Market skepticism: Some analysts argue the Wegovy pill may not be a game‑changer for long‑term revenue vs. injectables and competitive pressures, tempering expectations for sustained upside. Wegovy pill is not a game changer (Seeking Alpha)

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Rothschild & Co Redburn raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday, December 29th. Sanford C. Bernstein raised Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, September 9th. Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Finally, Hsbc Global Res cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, eleven have given a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and an average target price of $53.33.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $56.21 on Wednesday. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $93.80. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. The firm has a 50-day moving average of $49.22 and a two-hundred day moving average of $55.45. The company has a market capitalization of $250.98 billion, a price-to-earnings ratio of 16.34 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The business had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. As a group, analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.